BCAX
Price
$14.24
Change
-$0.67 (-4.49%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
780.09M
Intraday BUY SELL Signals
XENE
Price
$40.04
Change
+$0.36 (+0.91%)
Updated
Nov 13 closing price
Capitalization
3.09B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAX vs XENE

Header iconBCAX vs XENE Comparison
Open Charts BCAX vs XENEBanner chart's image
Bicara Therapeutics
Price$14.24
Change-$0.67 (-4.49%)
Volume$13.94K
Capitalization780.09M
Xenon Pharmaceuticals
Price$40.04
Change+$0.36 (+0.91%)
Volume$967.26K
Capitalization3.09B
BCAX vs XENE Comparison Chart in %
View a ticker or compare two or three
VS
BCAX vs. XENE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAX is a Hold and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (BCAX: $14.91 vs. XENE: $39.68)
Brand notoriety: BCAX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAX: 93% vs. XENE: 84%
Market capitalization -- BCAX: $780.09M vs. XENE: $3.09B
BCAX [@Biotechnology] is valued at $780.09M. XENE’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAX’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • BCAX’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than BCAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAX’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • BCAX’s TA Score: 4 bullish, 5 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than BCAX.

Price Growth

BCAX (@Biotechnology) experienced а +5.45% price change this week, while XENE (@Biotechnology) price change was +2.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

XENE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.09B) has a higher market cap than BCAX($780M). XENE YTD gains are higher at: 1.224 vs. BCAX (-14.409). BCAX has higher annual earnings (EBITDA): -121M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. BCAX (437M). BCAX has less debt than XENE: BCAX (2.24M) vs XENE (8.72M). XENE has higher revenues than BCAX: XENE (7.5M) vs BCAX (0).
BCAXXENEBCAX / XENE
Capitalization780M3.09B25%
EBITDA-121M-315.5M38%
Gain YTD-14.4091.224-1,177%
P/E Ratio2.65N/A-
Revenue07.5M-
Total Cash437M488M90%
Total Debt2.24M8.72M26%
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
36
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCAXXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 7 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BCAX
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMOIX33.780.26
+0.78%
GMO International Equity III
IGFSX10.890.01
+0.09%
VY® Morgan Stanley Global Franchise S2
FZANX52.03N/A
N/A
Fidelity Advisor New Insights Z
FIRAX10.29N/A
N/A
Fidelity Advisor Intl Real Estate A
ETCGX52.51-0.04
-0.08%
Eventide Gilead C

BCAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with IMNM. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAX
1D Price
Change %
BCAX100%
+1.22%
IMNM - BCAX
42%
Loosely correlated
-0.51%
SYRE - BCAX
41%
Loosely correlated
+0.34%
TIL - BCAX
39%
Loosely correlated
-4.83%
VYGR - BCAX
39%
Loosely correlated
-0.23%
XENE - BCAX
39%
Loosely correlated
-0.60%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.60%
NUVL - XENE
61%
Loosely correlated
+0.91%
IDYA - XENE
57%
Loosely correlated
-0.19%
NRIX - XENE
54%
Loosely correlated
-5.37%
DNLI - XENE
51%
Loosely correlated
-0.34%
CRNX - XENE
51%
Loosely correlated
-0.28%
More